New products from Israeli companies specializing in biotech, pharma, and medical devices were showcased at ILSI Biomed 2010, this year’s Israeli Life Science’s Conference.
Extensive cooperation between academia and business, an entrepreneurial spirit and a highly-skilled workforce have all contributed to the creation of Israel’s strong biotech industry.
Israel’s thriving life sciences industry includes more than 1,000 companies developing innovations in biotech, pharma and medical devices. Many of these companies presented their newest products at the latest ILSI Biomed 2010 from June 14 to 16, attended by more than 1,000 international visitors.
ISRAEL21c’s Harvey Stein visited the booths and learned about innovations like a sensor based on fiber optics that radically simplifies the identification of cancerous tissue from the start-up OptiVasive.
Nesher-based NanoVibronix has the only patch-based, personal therapeutic ultrasound device on the market, for the treatment of pain, burns, wounds and soft-tissue injury. The device already has regulatory approvals, such as the C mark in Europe and FDA approval for pain indication.
Mazal Plant Pharmaceuticals is the first company to receive FDA approval to start clinical trials for a whole plant pharmaceutical. Company president Meir Silver Ph.D. tells ISRAEL21c that Mazal is using a formulation of seven different whole plants to create a drug that is being used to influence cholesterol levels to decrease cardiovascular risks. The company hopes to treat disease using natural means.
Check out our video for more data about cutting-edge biomed innovations from Israel.